Download View Dr. Jonine Figueroa`s Resume / CV

JONINE DANYA FIGUEROA
Chancellor’s Fellow
Usher Institute of Population Health Sciences and Informatics
The University of Edinburgh
Medical School, Teviot Place
Edinburgh, EH8 9AG
Tel: +44 (0)131 651 4140
Cel: +44 (0)747 846 7698
Email: [email protected]
PROFESSIONAL INTERESTS
Tissue biomarkers related to breast cancer development and genetic susceptibly loci for breast and
bladder cancers
EDUCATION
1998
2004
2005
B.S. (Genetics and Developmental Biology), The Pennsylvania State University,
State College, PA
Ph.D. (Molecular Genetics and Microbiology), Stony Brook University, Stony
Brook, NY
M.P.H. (Epidemiology), Columbia University, New York, NY
EMPLOYMENT HISTORY
1995
1996
1997
1999-04
2004-05
2005-08
2008
2008-2015
2015-
Undergraduate Research Student, Department of Biology, University Park, PA
Cooperative Education Program, Janssen Research Foundation, Oncology Division,
Spring House, PA
Summer Research Internship, DuPont Agricultural Products, Stine-Haskell Newark,
DE
Graduate Student, Department of Molecular Genetics and Microbiology, Stony
Brook University, Stony Brook, NY
Research Assistant, Department of Epidemiology, Columbia University, New York,
NY
Cancer Prevention Postdoctoral Fellow, Preceptor: Dr. Montserrat Garcia-Closas,
Hormonal and Reproductive Epidemiology Branch (HREB), National Cancer
Institute (NCI), National Institutes of Health (NIH), Bethesda, MD
Research Fellow, HREB, NCI, NIH, Bethesda, MD
Investigator, HREB, NCI, NIH, Bethesda, MD
Chancellor’s Fellow, Usher Institute of Population Health Sciences and Informatics,
The University of Edinburgh, Edinburgh, UK
RESEARCH FUNDING AWARDS
JDF-1
2007
2007
2009
2010
2013
“Evaluation of estrogen receptor coregulators with breast cancer risk and tumor
characteristics”, NCI Director’s Intramural Innovation Career Development Award,
$10,000, PI: Jonine Figueroa
“Evaluation of estrogen receptor coregulators with breast cancer risk and tumor
characteristics”, NCI/ Division of Cancer Epidemiology and Genetics (DCEG),
Intramural Research Award, $40,000, PI: Jonine Figueroa
“Breast Cancer Risk Factors and Markers of Proliferation, Apoptosis and Hormone
Receptor Expression in Normal Breast Biopsies”, NCI/DCEG Intramural Research
Award, $50,000, PI: Jonine Figueroa
“Profiling TP53 somatic alterations and autoantibodies: Associations with risk
factors among estrogen receptor-negative breast cancer cases in the Polish Breast
Cancer Study “, NCI Director’s Intramural Innovation Award, $50,000, PI: Jonine
Figueroa
“Molecular tumor characteristics of breast cancers in Ghana”, Administrative
Supplements to NCI-Funded Research Projects: Funding to Advance Research on
Cancers in Women, $46,500, PI: Jonine Figueroa
TEACHING AND MENTORING
Mentored following students during the course of post-baccalaureate training:
2010-2012
2012-2013
2014-2015
Laura Linville, B.S., Intramural Research Training Award Fellow
Daphne Papathomas, B.S., Intramural Research Training Award Fellow
Jackie Zhang, B.S., Intramural Research Training Award Fellow
Mentored following student during the course of master’s work:
2009-2010
Aileen Burke, M.P.H., Intramural Research Training Award Fellow
Mentored following scientists for postdoctoral training:
2010-present Sarah Nyante, Ph.D., M.S.P.H., Cancer Research Training Award Fellow
-2010 NIH Fellow Award for Research Excellence (FARE)
-2010 American Association for Cancer Research Minority Scholars scholarship
supported by Susan G. Komen for the Cure® San for travel to Antonio Breast
Cancer Symposium Meeting
2011-2014
Hisani Horne, Ph.D., M.P.H., Cancer Prevention Fellow
-2012 American Association for Cancer Research Minority Scholars scholarship
supported by Susan G. Komen for the Cure® for travel to San Antonio Breast
Cancer Symposium Meeting
2012-2014
Zeina Khodr, Ph.D., M.P.H., Cancer Research Training Fellow
-2012 American Association for Cancer Research Scholar in Training Award for
Frontiers in Cancer Prevention meeting
2014-present Hannah Oh, Ph.D., M.P.H., Cancer Research Training Fellow
2013-2015
Stella Koutros Ph.D., M.P.H., Research Fellow
JDF-2
Mentored following student for Masters of Public Health Degree Thesis:
2009-2010
Aileen Burke, M.P.H., IRTA fellow
Mentored following students for post-baccalaureate training:
2010-2012
Laura Linville, B.S., IRTA fellow
-2011 DCEG Fellow Award for Research Excellence (DFARE)
2012-2013
Daphne Papathomas, B.S., IRTA fellow
-2012-2013 NIH Academy Fellow
Selected seminars to students/trainees:
2007
2007/2008
2008-2010
2010
2011
2011
2012-2014
Lectured on genetic association study design, analysis and interpretation, George
Washington University Molecular Epidemiology Course, Washington, DC
Lectured on expression and tissue microarrays in epidemiology research, George
Washington University Molecular Epidemiology Course, Washington, DC
Lectured on occupational, environmental, and genetic susceptibility risk factors for
bladder cancer, NCI Summer Curriculum on Cancer Prevention: Principles and
Practice of Cancer Prevention and Control Course, Rockville, MD
Lectured on TGF-and breast cancer risk and opportunities in molecular
epidemiology, NCI, Hispanic Youth Initiative, Bethesda, MD
Lectured on molecular markers in population studies, NCI Summer Curriculum on
Cancer Prevention: Principles and Practice of Cancer Prevention and Control
Course, Molecular Prevention Course, Rockville, MD
Lectured on molecular epidemiology of breast cancer, Stony Brook University,
Stony Brook, NY
Lectured on tissue-based markers in population studies, NCI Summer Curriculum on
Cancer Prevention: Principles and Practice of Cancer Prevention and Control
Course, Molecular Prevention Course, Rockville, MD
FELLOWSHIPS AND SCHOLARSHIPS
1993-1998
1998-2004
2000-2004
2004-2008
2015
Pennsylvania State Honors Scholarship
W. Burghardt Turner Doctoral Fellowship, Stony Brook University, NY
Predoctoral Fellowship, NCI Cancer Biology training grant, Stony Brook University,
NY
NCI Cancer Prevention Fellowship, NCI, Bethesda, MD
Chancellor’s Fellowship, University of Edinburgh, UK
PROFESSIONAL HONORS AND RECOGNITION
2003
2006
2006
2007
Stony Brook University, Department of Molecular Genetics and Microbiology
Distinguished Service Award
Keystone Meeting Minority Travel Scholarship for Genome Instability and Repair
NIH Fellows Award for Research Excellence
NCI Cancer Prevention Research Training Merit Award
JDF-3
2007
2007
2009
2010
2013
2015
NCI Director’s Intramural Innovation Career Development Award
NCI/ Division of Cancer Epidemiology and Genetics (DCEG), Intramural Research
Award
NCI/DCEG Intramural Research Award
NCI Director’s Intramural Innovation Award
Administrative Supplements to NCI-Funded Research Projects: Funding to Advance
Research on Cancers in Women
NCI Director’s Award
PROFESSIONAL MEMBERSHIP
2005-present American Association for Cancer Research
ELECTED OFFICES
1998
2000
2001-04
2008
2014-2016
Founder and President, Minorities in Science & Technology, The Pennsylvania State
University
Chair, Underrepresented Graduate Scholars, Stony Brook University
Graduate Student Representative, The Department of Molecular Genetics and
Microbiology, Stony Brook University
DCEG Fellows Colloquium Planning Committee, HREB representative
Member, American Association for Cancer Research, Molecular Epidemiology
Working Group (MEG) steering committee
JOURNAL EDITORIAL SERVICE
2011-present Review Editor, Frontiers in Cancer Epidemiology and Prevention
Reviewer, American Journal of Epidemiology, BMC Cancer, Breast Cancer Research, Breast
Cancer Research and Treatment, British Journal of Cancer, Cancer Epidemiology Biomarkers and
Prevention, Cancer Letters, Cancer Research, Carcinogenesis, Clinical Cancer Research, European
Journal of Cancer, Human Molecular Genetics, Human Genetics, Human Immunology, Journal of
the National Cancer Institute, Molecular Carcinogenesis, Nature Protocols, New England Journal of
Medicine
SCIENTIFIC LEADERSHIP AND SERVICE
2006
2007
2008
2008
2008
2009
Organizing committee, 5th Annual Cancer Prevention Fellows’ Scientific
Symposium. Cancer Prevention and Control: the Next Generation.
Chief Judge, NIH Fellows Award for Research Excellence, Genomics review session
Alternate Judge, for NIH Fellows Award for Research Excellence (FARE)
Genomics review session
Member, Cancer Prevention Fellows Advisory Board
Member, NCI Outstanding Mentor Award Selection Committee
Member, Division of Cancer Epidemiology and Genetics Tenure-track Selection
Committee, HREB representative
JDF-4
2009-2010
2010
2010
2013
2013
2013
2011-2015
Member, Division of Cancer Epidemiology and Genetics Biorepository Committee,
HREB representative
Member, Division of Cancer Epidemiology and Genetics Tenure-track Selection
Committee, Laboratory of Translational Genomics
Member, Division of Cancer Epidemiology and Genetics, Genotyping Review
Committee, HREB representative
Member, Division of Cancer Epidemiology and Genetics, Technical Evaluation of
Protocols, HREB representative
Co-Director, Division of Cancer Epidemiology and Genetics, Molecular
Epidemiology Course
Member, American Association for Cancer Research, Molecular Epidemiology
Working Group (MEG) strategic planning session
Member, Division of Cancer Epidemiology and Genetics, Cancer Genetic Markers
of Susceptibility Data Access Review Committee, HREB representative
GRANT/PROJECT REVIEWER ACTIVITIES
2012
2013
2013
Reviewer, Administrative Supplements to NCI-Funded Research Projects: Funding
to Advance Research on Cancers in Women
Reviewer, Prostate, Lung, Colorectal, Ovarian (PLCO) Screening Trial, Etiology and
Early Marker Studies (EEMS) review panel
Reviewer, Komen’s Investigator Initiated Research/Career Catalyst Research Grants
for Highly Exposed Populations and New Exposure Assessment Tools
CONTRIBUTED PRESENTATIONS
Poster presentations
9/95 The National Science Foundation Conference on Diversity in the Scientific and
Technological Workforce, Mosaic analysis of the Delayed Furrow gene in Drosophila Eye
development, Washington, DC
8/02
Annual Biomedical Research Conference for Minority Sudents (ABRCMS), Colocalization
of c-Ski and the Ski-interacting protein (Skip) in C2C12 cells,. New Orleans, LA
7/03
The Federation of American Societies for Experimental Biology (FASEB) The TGF-beta
Superfamily: Signaling and Development, Negative Regulation of BMP-2 Mediated
Osteoblast Differentiation Of C2C12 Cells By The Ski-Interacting Protein (SKIP), Tuscon,
AZ
4/06
American Association for Cancer Research Annual Meeting, Genetic variation in
carcinogen metabolizing enzymes and bladder cancer risk. Washington, DC
2/06
Keystone Meeting on Genomic Stability and Repair, Evaluation of genetic variation in the
double-strand break repair pathway suggests an association with bladder cancer risk,
Breckenridge, CO
JDF-5
6/ 07 American Association for Cancer Research: Approaches to Complex Pathways in Molecular
Epidemiology, Assessment of genetic variation in carcinogen metabolizing genes suggests
associations with bladder cancer risk, Santa Ana Pueblo, NM
4/06
American Association for Cancer Research Annual Meeting, Genetic variation in genes
participating in apoptosis and bladder cancer risk, San Diego, CA
9/08
Anita Roberts Symposium, TGF-β: Discovery and Promise, Evaluation of breast tumor
tissue expression of TGF- factors with tumor characteristics and risk factors in a
population-based study from Poland, Bethesda, MD
9/09
American Association for Cancer Research: Health Disparities Meeting, Relationships
between expression of TGF- factors and breast tumor characteristics in a populationbased study, Phoenix, AZ
4/11
American Association for Cancer Research Annual Meeting, Associations of common
variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by
tumor subtype: Findings from the Breast Cancer Association Consortium, Orlando, FL
4/12
American Association for Cancer Research Annual Meeting, Breast cancer risk factor
associations with breast tissue morphometry: results from the Komen for the Cure® Tissue
Bank, Chicago, IL
11/12 American Association for Cancer Research Molecular Epidemiology Working Group
Meeting: Post-GWAS Horizons in Molecular Epidemiology, Associations between breast
cancer susceptibility markers and terminal duct lobular unit involution in normal breast
tissues among women from the Susan G. Komen for the Cure® Tissue Bank, Hollywood, FL
11/13 American Association for Cancer Research International Conference on Frontiers in Cancer
Prevention Research, Determinants of terminal duct lobular unit (TDLU) involution of the
normal breast, National Harbor, MD
12/13 American Association for Cancer Research Conference on The Science of Cancer Health
Disparities in Ethnic Minorities and the Medically Underserved, Impact of pathologic
specimen quality on classifying molecular subtypes of breast cancer: A pilot study from
three hospitals in Ghana, Africa, Atlanta, GA
11/15 National Cancer Research Institute, Standardized measures of lobular involution and
subsequent breast cancer risk, Liverpool, UK
Platform presentations
4/15
American Association for Cancer Research Annual Meeting, Standardized measures of
lobular involution and subsequent breast cancer risk. Mini-symposium on “Molecular and
genetic epidemiology of cancer 4: New insights, Philadelphia, PA
JDF-6
12/15 United Kingdom Molecular Epidemiology Group Winter Meeting, The ageing breast:
implications for breast cancer aetiology. Newcastle upon Tyne, UK
INVITED PRESENTATIONS
8/07
Third Annual Bladder Consortium Meeting, Findings from Comprehensive Analysis of
NQO1, CYP1A1, and CYP1B1 from the Spanish Bladder Cancer Study, Barcelona, Spain
9/08
Cancer Prevention and Control Colloquia Series, DNA Repair and Bladder Cancer Risk:
Evaluating the Evidence, Rockville, MD
4/10
Breast Cancer Association Consortium (BCAC) Meeting, Analysis of SNPs rs11249433
(1p.11.2) and Two Highly Correlated SNPs (rs999737or rs10483813, r2=0.98) at 14q24.1
(RAD51L1) in BCAC, Cambridge, United Kingdom
12/10 International Consortium of Bladder Cancer Meeting, Pathway Based Analysis of Common
Genetic Variation, Houston, TX
9/11
7th Early Detection Research Network (EDRN) Scientific Workshop, Breast and
Gynecological Cancers Collaborative Group Meeting, Risk Factors for Triple-negative
Breast Cancer, Herndon, VA
9/12
Breast Cancer Association Consortium (BCAC) Meeting, Fine-mapping of Breast Cancer
Susceptibility Regions 1p.11.2 and 14q24.1 (RAD51L1) in iCOGs, Quebec City, Canada
10/12 International Consortium of Bladder Cancer Meeting, Genome-wide Association Study of
Bladder Cancer, Madrid, Spain
11/12 Division of Extramural Activities, Seminar Series, Molecular Markers in Population
Studies, Rockville, MD
4/13
Breast Cancer Association Consortium (BCAC) Meeting, E-Cadherin Tumor Expression
and Heterogeneity by Breast Cancer Susceptibility Loci, Quebec City, Canada
5/13
University of Chicago, Department of Health Studies Seminar Series, Etiologic
Heterogeneity of Breast Cancer, Chicago, IL
12/13 American Cancer Society, Epidemiology Research Program Seminar Series, The Use of
Molecular Pathology to Clarify Breast Cancer Etiology, Atlanta, GA
1/14
Columbia University, Mailman School of Public Health, Department of Epidemiology
Seminar Series, The Ghana Breast Health Study: A Molecular Epidemiology Study of Breast
Cancer in Ghana, Africa, New York, NY
JDF-7
4/14
American Association for Cancer Research Annual Meeting, Methods Workshop Session,
Pathoepidemiology of Breast Cancer, Value of Collecting Normal Tissue, San Diego, CA
4/14
American Association for Cancer Research Annual Meeting, Co-Chairperson, Recent
Advances in Molecular and Genetic Epidemiology, San Diego, CA
4/15
American Association for Cancer Research Annual Meeting, Moderator, MEG Networking
Event (with early-career investigators); the future of molecular epidemiology in the omics
era, Philadelphia, PA
11/15 National Health Services Lothian and the University of Edinburgh, Edinburgh Radiotherapy
Research Collaborative, Image analysis of mammograms and breast tissues. Edinburgh, UK
11/15 Clinical-academic breast team seminar series, University of Dundee, Lobular involution and
its implications in the natural history of breast cancer. Dundee, UK
BIBLIOGRAPHY
PEER-REVIEWED
1.
Leong GM, Subramaniam N, Figueroa J, Flanagan JL, Hayman MJ, Eisman, JA, Kouzmenko
A. Ski-interacting protein interacts with Smad proteins to augment transforming growth
factor-beta-dependent transcription. J Biol Chem 2001;276:18243-8.
2.
Figueroa JD and Hayman MJ. Differential regulation of the Ski-interacting protein (SKIP) on
differentiation induced by transforming growth factor-beta1 and bone morphogenetic protein2 in C2C12 cells. Exp Cell Res 2004;296:163-72.
3.
Figueroa JD and Hayman MJ. The human Ski-interacting protein functionally substitutes for
the yeast PRP45 gene. Biochem Biophys Res Commun 2004;319:1105-9.
4.
Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R,
Dosemeci M, Lan Q, Tardón A, Serra C, Carrato A, García-Closas R, Castaño-Vinyals G,
Rothman N, Garcia-Closas M. Genetic variation in base-excision repair enzymes and bladder
cancer risk. Hum Genet 2007;121:233-42.
5.
García-Closas M, Malats N, Real FX, Welch R, Yeager M, Silverman D, Kogevinas M,
Chatterjee N, Dosemeci M, Figueroa JD, Tardón A, Serra C, Carrato A, García Closas R,
Castaño Vinyals G, Rothman N, Chanock S. Large-scale evaluation of candidate genes
identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet
2007;3:e29.
6.
Figueroa JD, Malats N, Rothman N, Real FX, Silverman D, Kogevinas M, Chanock S,
Welch R, Dosemeci M, Lan Q, Tardón A, Serra C, Carrato A, García-Closas R, Castaño-
JDF-8
Vinyals G, Garcia-Closas M. Evaluation of genetic variation in the double-strand break repair
pathway and bladder cancer risk. Carcinogenesis 2007;28:1788-93.
7.
Danforth KN, Hayes RB, Rodriguez C, Sakoda LC, Huang WH, Yu K, Chen BE, Chen J,
Andriote GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, Michaud DS,
Chanock SJ, Thun MJ, Hsing AW. Polymorphic variants in PTGS2 and prostate cancer risk:
Results from two large nested case-control studies. Carcinogenesis 2008;29:568-72.
8.
Danforth KN, Hayes RB, Rodriguez C, Sakoda LC, Huang WH, Yu K, Chen BE, Chen J,
Andriote GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, Michaud DS,
Chanock SJ, Thun MJ, Hsing AW. TNF polymorphisms and prostate cancer risk. Prostate
2008;68:400-7.
9.
Landi MT, Dracheva T, Rotunno M, Figueroa JD, Shih J, Consonni D, Pesatori A,
Wacholder S, Bertazzi PA, Caporaso N, Jen J. Gene expression signature of cigarette smoking
and its role in lung adenocarcinoma development and survival. PLoS One 2008;3:e1651.
PMCID: PMC2249927.
10.
Figueroa JD, Malats N, Garcia-Closas M , Real FX, Silverman D, Kogevinas M, Chanock S,
Welch R, Dosemeci M, Lan Q, Tardón A, Serra C, Carrato A, García-Closas R, CastañoVinyals G, Rothman N. Bladder cancer risk and genetic variation in AKR1C3 and other
metabolizing genes. Carcinogenesis 2008;29:1955-62. PMCID: PMC2556968.
11.
Figueroa JD, Sakoda LC, Graubard BI, Chanock S, Rubertone MV, Erickson RL, McGlynn
KA. Genetic variation in hormone metabolizing genes and risk of testicular germ cell tumors.
Cancer Causes Control 2008;19:917-29.
12.
Figueroa JD, Terry MB, Gammon MD, Zhang FF, Vaughn TL, Risch HA, Kleiner D,
Bennett WP, Fraumeni JF Jr., Chow WH. Cigarette smoking, body mass index, gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes
of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control
2009;20:361-8. PMCID: PMC2726999.
13.
Chia VM, Li Y, Quraishi SM, Graubard BI, Figueroa JD, Weber JP, Chanock S, Rubertone
MV, Erickson RL, McGlynn KA. Effect modification of endocrine disruptors and testicular
germ cell tumour risk by hormone-metabolizing genes. Int J Androl 2010; 33:588-96.
PMCID: PMC2891172.
14.
Stern MC*, Lin J*, Figueroa JD*, … Garcia-Closas M. Polymorphisms in DNA repair
genessmoking, and bladder cancer risk: Findings from the International Consortium of
Bladder Cancer. Cancer Res 2009;69:6857-64. PMCID: PMC2782435. *These authors have
contributed equally to the analyses and writing of the manuscript.
15.
Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, Brinton LA,
Rimm DL, Laird PW, Garcia-Closas M, Sherman ME. DNA hypermethylation of ESR1 and
PGR in breast cancer: Pathologic and epidemiologic associations. Cancer Epidemiol
Biomarkers Prev 2009;18:3036-43. PMCID: PMC2783691.
JDF-9
16.
Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK,
Duggan M, Pfeiffer RM, Ooshima A, Cornelison R, Gierach GL, Brinton LA, Lissowska J,
Peplonska B, Wakefield LM, Sherman ME. Expression of TGF-beta signaling factors in
invasive breast cancers: Relationships with age at diagnosis and tumor characteristics. Breast
Cancer Res Treat 2010;121:727-35. NIHMSID: NIHMS616639.
17.
Yang HP, Gonzalez Bosquet J, Li Q, Platz EA, Brinton LA, Sherman ME, Lacey JV Jr,
Gaudet MM, Burdette LA, Figueroa JD, Ciampa JG, Lissowska J, Peplonska B, Chanock SJ,
Garcia-Closas M. Common genetic variation in the sex hormone metabolic pathway and
endometrial cancer risk: Pathway-based evaluation of candidate genes. Carcinogenesis
2010;31:827-33. PMCID: PMC2864407.
18.
Bolton KL, Garcia-Closas M, Pfeiffer RM, Duggan MA, Howat WJ, Hewitt SM, Yang XR,
Cornelison R, Anzick SL, Meltzer P, Davis S, Lenz P, Figueroa JD, Pharoah PD, Sherman
ME. Assessment of automated image analysis of breast cancer tissue microarrays for
epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2010;19:992-9. PMCID:
PMC2852578.
19.
Menashe I, Maeder D, Garcia-Closas M, Figueroa JD, Bhattacharjee S, Rotunno M, Kraft P,
Hunter DJ, Chanock SJ, Rosenberg PS, Chatterjee N. Pathway analysis of breast cancer
genome-wide association study highlights three pathways and one canonical signaling
cascade. Cancer Res 2010;70:4453-9. PMCID:PMC2907250.
20.
Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A,
Pfeiffer RM, Yang XR Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD.
Prolactin serum levels and breast cancer: Relationships with risk factors and tumour
characteristics among pre and postmenopausal women in a population-based case-control
study from Poland. Br J Cancer 2010;103:1097-102. PMCID: PMC2965860.
21.
Cantor KP, Villanueva CM, Silverman DT, Figueroa JD, Real FX, Garcia-Closas M, Malats
N, Chanock S, Yeager M, Tardón A, García-Closas R, Serra C, Carrato A, Castaño-Vinyals
G, Samanic C, Rothman N, Kogevinas M. Polymorphisms in GSTT1, GSTZ1, and CYP2E1,
disinfection byproducts, and risk of bladder cancer in Spain. Environ Health Perspect
2010;118:1545-50. PMCID: PMC2974691.
22.
Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD (writing
group),… Chanock SJ. A multi-stage genome-wide association study of bladder cancer
identifies multiple susceptibility loci. Nat Genet 2010;42:978-84. PMCID: PMC3049891.
23.
Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson
AT, Lubin JH, Hein DW, Dagnall CL, Colt JS, Kida M, Jones MA, Schned AR, Cherala SS,
Chanock SJ, Cantor KP, Silverman DT, Rothman N. GSTM1 null and NAT2 slow acetylation
genotypes, smoking intensity, and bladder cancer risk: Results from the New England Bladder
Cancer Study and NAT2 meta-analysis. Carcinogenesis 2011;32:182-9. PMCID:
PMC3026839.
JDF-10
24.
Milne RL, Gaudet MM, Spurdle AB, … Figueroa J, … Chang-Claude J. Assessing
interactions between the associations of common genetic susceptibility variants, reproductive
history and body mass index with breast cancer risk in the Breast Cancer Association
Consortium: a combined case-control study. Breast Cancer Res 2010;12:R110. PMCID:
PMC3046455.
25.
Garcia-Closas M, Hein DW, Silverman D, Malats N, Yeager M, Jacobs K, Doll MA,
Figueroa JD, Baris D, Schwenn M, Kogevinas M, Johnson A, Chatterjee N, Moore L,
Moeller T, Real FX, Chanock S,Rothman N. A single nucleotide polymorphism tags variation
in the arylamine N-acetyltransferase 2 phenotype in populations of European background.
Pharmacogenet Genomics 2011;21:231-6. PMCID: PMC3003749.
26.
†Nyante
27.
Yang XR, Chang-Claude J, Goode EL, … Figueroa J, … Garcia-Closas, M. Associations of
breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer
Association Consortium studies. J Natl Cancer Inst 2011;103:250-63. PMCID: PMC3107570.
28.
Lin WY, Camp NJ, Cannon-Albright LA, … Figueroa J, … Cox A. A role for XRCC2 gene
polymorphisms in breast cancer risk and survival. J Med Genet 2011;48:477-84. PMCID:
PMC3932658.
29.
Broeks A, Schmidt MK, Sherman ME, … Figueroa J, … Garcia-Closas M. Low penetrance
breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings
from the Breast Cancer Association Consortium. Hum Mol Genet 2011;20:3289-303.
PMCID: PMC3140824.
30.
Scollen S, Luccarini C, Baynes C, Driver K, Humphreys MK, Garcia-Closas M, Figueroa J,
Lissowska J, Pharoah PD, Easton DF, Hesketh R, Metcalfe JC, Dunning AM. TGF-beta
signaling pathway and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev
2011;20:1112-9. PMCID: PMC3112459.
31.
Milne RL, Goode EL, García-Closas M, … Figueroa JD, … Easton DF. Confirmation of
5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
Cancer Epidemiol Biomarkers Prev 2011;20:2222-31. NIHMSID: NIHMS493090.
32.
Garcia-Closas M*, Ye Y*, Rothman N*, Figueroa JD*, … Wu X. A genome-wide
association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a
urea transporter gene on chromosome 18q12.3. Hum Mol Genet 2011;20:4282-9. PMCID:
PMC3188994. *These authors contributed jointly to this work.
S, Faupel-Badger J, Sherman ME, Pfeiffer RM, Gaudet MM, Falk RT, Andaya AA,
Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Chanock S, Garcia-Closas M,
Figueroa JD. Genetic variation in PRL and PRLR, and relationships with serum prolactin
levels and breast cancer risk: Results from a population-based case-control study in Poland.
Breast Cancer Res 2011;13(2):R42. PMCID: PMC3219205.
JDF-11
33.
Figueroa JD, Garcia-Closas M, Humphreys M, ... Spurdle AB. Associations of common
variants in 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor
subtype: Findings from the Breast Cancer Association Consortium. Hum Mol Genet
2011;20:4693-706. PMCID: PMC3209823.
34.
Falk RT, Gentzschein E, Stanczyk FZ, Garcia-Closas M, Figueroa JD, Ioffe OB, Lissowska
J, Brinton LA, Sherman ME. Sex steroid hormone levels in breast adipose tissue and serum in
postmenopausal women. Breast Cancer Res Treat 2012;131:287-94. NIHMSID:
NIHMS618118.
35.
Lee P, Fu YP, Figueroa JD, … Chanock SJ. Fine mapping of 14q24.1 breast cancer
susceptibility locus. Hum Genet 2012; 131:479-90. NIHMSID: NIHMS616599.
36.
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C,
Love R, Schiff R, Rimm DL. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res
2012;18:118-26. PMCID: PMC3263348.
37.
Menashe I*, Figueroa JD*, Garcia-Closas M, … Rothman N. Large-scale pathway-based
analysis of bladder cancer genome-wide association data from five studies of European
background. PLoS One 2012;7:e29396. PMCID: PMC3251580. *These authors contributed
jointly to this work.
38.
Tang W, Fu YP, Figueroa JD, … Prokunina-Olsson L. Mapping of the UGT1A locus
identifies an uncommon coding variant that affects mRNA expression and protects from
bladder cancer. Hum Mol Genet 2012;21:1918-30. PMCID: PMC3313801.
39.
Ghoussaini M, Fletcher O, Michailidou K, … Figueroa JD, … Easton DF. Genome-wide
association analysis identifies three new breast cancer susceptibility loci. Nat Genet
2012;44:312-8. PMCID: PMC3653403.
40.
Stevens KN, Fredericksen Z, Vachon CM, … Figueroa JD, … Couch FJ. 19p13.1 is a triple
negative-specific breast cancer susceptibility locus. Cancer Res 2012;72:1795-803.
PMC3319792.
41.
Sherman ME, Figueroa JD, Henry JE, Clare SE, Rufenbarger C, Storniolo AM. The Susan G.
Komen for the Cure Tissue Bank at the IU Simon Cancer Center: A unique resource for
defining the "molecular histology" of the breast. Cancer Prev Res 2012;5:528-35. NIHMSID:
NIHMS616983.
42.
Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y (writing group),… ProkuninaOlsson L. Common genetic variants in the PSCA gene influence gene expression and bladder
cancer risk. Proc Natl Acad Sci USA 2012;109:4974-9. PMCID: PMC3324016.
43.
Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, Fischer AH, Figueroa JD,
Berndt SI, Han S, Beane Freeman LE, Lubin JH, Cherala S, Cantor KP, Jacobs K, Chanock S,
Chatterjee N, Rothman N, Silverman DT. Non-steroidal anti-inflammatory drugs and other
JDF-12
analgesic use and bladder cancer in northern New England. Int J Cancer 2013;132:162-73.
PMCID: PMC3951299.
44.
Yang XR, Figueroa JD, Falk RT, Zhang H, Pfeiffer RM, Hewitt SM, Lissowska J, Peplonska
B, Brinton L, Garcia-Closas M, Sherman ME. Analysis of terminal duct lobular unit (TDLU)
involution in luminal A and basal breast cancers. Breast Cancer Res 2012; Apr 18;14(2):R64.
PMCID: PMC3446399.
45.
Fasching PA, Pharoah PD, Cox A, … Figueroa JD, … Schmidt MK. The role of genetic
breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012;21:3926-39.
PMCID: PMC3412377.
46.
Jacobs KB, Yeager M, Zhou W, … Figueroa JD, … Chanock SJ. Detectable clonal
mosaicism and its relationship to aging and cancer. Nat Genet 2012;44:651-8. PMCID:
PMC3372921.
47.
Hein R, Maranian M, Hopper JL, … Figueroa JD, … Dunning AM. Comparison of 6q25
Breast cancer hits from Asian and European Genome Wide Association Studies in the Breast
Cancer Association Consortium (BCAC). PLoS One 2012;7(8):e42380. PMCID:
PMC3413660.
48.
Vachon CM, Scott CG, Fasching PA, … Figueroa JD, … dos-Santos-Silva I. Common breast
cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic
density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev
2012;21:1156-66. PMCID: PMC3569092.
49.
Hüsing A, Canzian F, Beckmann L, … Figueroa JD, … Kaaks R; BPC3. Prediction of breast
cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet
2012;49:601-8. PMCID: PMC3793888.
50.
Jamshidi M, Schmidt MK, Dörk T, … Figueroa J, … Nevanlinna H. Germline variation in
TP53 regulatory network genes associates with breast cancer survival and treatment outcome.
Int J Cancer 2013;132:2044-55. NIHMSID: NIHMS616636.
51.
Siddiq A, Couch FJ, Chen GK, … Figueroa JD, … Vachon CM. A meta-analysis of genomewide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and
20q11. Hum Mol Genet 2012;21:5373-84. PMCID: PMC3510753.
52.
Weischer M, Nordestgaard BG, Pharoah P, … Figueroa J, … Bojesen SE. CHEK2*1100delC
Heterozygosity in women with breast cancer associated with early death, breast cancerspecific death, and increased risk of a second breast cancer. J Clin Oncol 2012;30:4308-16.
PMCID: PMC3515767.
53.
Han SS, Rosenberg PS, Garcia-Closas M, Figueroa JD, Silverman D, Chanock SJ, Rothman
N, Chatterjee N. Likelihood ratio test for detecting gene (G)-environment (E) interactions
under an additive risk model exploiting G-E independence for case-control data. Am J
Epidemiol 2012;176:1060-7. PMCID: PMC3571244.
JDF-13
54.
Yang XR, Figueroa JD, Hewitt SM, Falk RT, Pfeiffer RM, Lissowska J, Peplonska B,
Brinton LA, Garcia-Closas M, Sherman ME. Estrogen receptor and progesterone receptor
expression in normal terminal duct lobular units surrounding invasive breast cancer. Breast
Cancer Res Treat 2013;137:837-47. NIHMSID: NIHMS619641.
55.
Andersen SW, Trentham-Dietz A, Figueroa JD, Garcia-Closas M, Titus-Ernstoff L, Cai Q,
Long J, Hampton JM , Egan KM, Newcomb PA. Breast cancer susceptibility associated with
rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a
population-based United States study. Menopause 2013;20:354-8. PMCID: PMC3549049.
56.
Meyer KB, O'Reilly M, Michailidou K, … Figueroa J, … Easton DF. Fine-scale mapping of
the FGFR2 breast cancer risk locus: Putative functional variants differentially bind FOXA1
and E2F1. Am J Hum Genet 2013;93:1046-60. PMCID: PMC3852923.
57.
Wang J, Barker K, Steel J, Park J, Saul J, Festa F, Wallstrom G, Yu X, Bian X, Figueroa J,
LaBaer J, Qiu J. A versatile protein microarray platform enabling antibody profiling against
denatured proteins. Proteomics Clin Appl 2013;7:378-83. PMCID: PMC4127978.
58.
Hendrickson SJ, Lindström S, Eliassen AH, … Figueroa JD, … Willett WC. Plasma
carotenoid- and retinol-weighted gene scores and risk of breast cancer in the National Cancer
Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev
2013 22:927-36. PMCID: PMC3650115.
59.
Michailidou K, Hall P, Gonzalez-Neira A, … Figueroa J, … Easton DF. Large-scale
genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45:35361. PMCID: PMC3771688.
60.
Bojesen SE, Pooley KA, Johnatty SE, … Figueroa J, … Dunning AM. Multiple independent
variants at the TERT locus are associated with telomere length and risks of breast and ovarian
cancer. Nat Genet 2013;45:371-84. PMCID: PMC3670748.
61.
Garcia-Closas M, Couch FJ, Lindstrom S, … Figueroa JD, … Kraft P. Genome-wide
association studies identify four ER negative-specific breast cancer risk loci. Nat Genet
2013;45:392-98. PMCID: PMC3771695.
62.
Garcia-Closas M, Rothman N, Figueroa JD, … Chatterjee N (writing group),…. Common
genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.
Cancer Res 2013;73:2211-20. PMCID: PMC3688270.
63.
French JD, Ghoussaini M, Edwards SL, … Figueroa J, … Dunning AM. Functional variants
at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range
enhancers. Am J Hum Genet 2013;92:489-503. PMCID: PMC3617380.
64.
Nickels S, Truong T, Hein R, … Figueroa J (writing group),…, … Chang-Claude J.
Evidence of gene-environment interactions between common breast cancer susceptibility loci
JDF-14
and established environmental risk factors. PLoS Genet 2013;9:e1003284. PMCID:
PMC3609648.
65.
Koutros S, Baris D, Fischer A, Tang W, Garcia-Closas M, Karagas MR, Schwenn M, Johnson
A, Figueroa J, Waddell R, Prokunina-Olsson L, Rothman N, Silverman DT. Differential
urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in
the urea transporter gene, SLC14A1. Int J Cancer 2013;133:3008-13. PMCID: PMC3797230.
66.
Li J, Foo JN, Schoof N, Varghese JS, Fernandez-Navarro P, Gierach GL, Quek ST, Hartman
M, Nord S, Kristensen VN, Pollán M, Figueroa JD, Thompson DJ, Li Y, Khor CC,
Humphreys K, Liu J, Czene K, Hall P. Large-scale genotyping identifies a new locus at
22q13.2 associated with female breast size. J Med Genet 2013;50:666-73. NIHMSID:
NIHMS616945.
67.
Rosebrock A, Caban JJ, Figueroa J, Gierach G, Linville L, Hewitt S, Sherman M.
Quantitative analysis of TDLUs using adaptive morphological shape techniques. In: Gurcan
MN, Madabhushi A, eds. Medical imaging 2013: digital pathology. Proceedings of SPIE, vol.
8676. Bellingham, WA: SPIE, 2013;8676 0N. NIHMSID: NIHMS618426.
68.
Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner
HG, Engelman CD, Klein BE, Titus LJ, Newcomb PA. The associations between a polygenic
score, reproductive and menstrual risk factors and breast cancer risk. Breast Cancer Res Treat
2013;140:427-34. PMCID: PMC3799826.
69.
Sun X, Gierach GL, Sandhu R, Williams T, Midkiff BR, Lissowska J, Wesolowska E, Boyd
NF, Johnson NB, Figueroa JD, Sherman ME, Troester MA. Relationship of mammographic
density and gene expression: Analysis of normal breast tissue surrounding breast cancer. Clin
Cancer Res 2013;19:4972-82. PMCID: PMC4073678.
70.
Rudolph A, Hein R, Lindström S, … Figueroa JD, … Chang-Claude J on behalf of the Breast
cancer Association Consortium. Genetic modifiers of menopausal hormone replacement
therapy and breast cancer risk: A genome-wide interaction study. Endocr Relat Cancer
2013;20:875-87. PMCID: PMC3863710.
71.
Gierach GL, Yang XR, Figueroa JD, Sherman ME. Emerging concepts in breast cancer risk
prediction. Curr Obstet Gynecol Rep 2013;2:43-52. NIHMSID: NIHMS617311.
72.
Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner
HG, Engelman CD, Klein BE, Titus LJ, Newcomb PA. The associations between a polygenic
score, reproductive and menstrual risk factors and breast cancer risk. Breast Cancer Res Treat
2013;140:427-34. PMCID: PMC3799826.
73.
Figueroa JD, Ye Y, Siddiq A, … Rothman N. Genome-wide association study identifies
multiple loci associated with bladder cancer risk. Hum Mol Genet 2014;23:1387-98. PMCID:
PMC3919005.
JDF-15
74.
Faupel-Badger JM, Duggan MA, Sherman ME, Garcia-Closas M, Yang XR, Lissowska J,
Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD. Prolactin receptor expression and
breast cancer: Relationships with tumor characteristics among pre- and post-menopausal
women in a population-based case-control study from Poland. Horm Cancer 2014;5:42-50.
PMCID: PMC3906637.
75.
†Horne HN,
76.
Ali AM, Schmidt MK, Bolla MK, … Figueroa J, … Pharoah PD. Alcohol consumption and
survival after a breast cancer diagnosis: A literature-based meta-analysis and collaborative
analysis of data for 29,239 cases. Cancer Epidemiol Biomarkers Prev 2014;23:934-45.
77.
Brinton LA, Figueroa JD, Awuah B, Yarney J, Wiafe S, Wood SN, Ansong D, Nyarko K,
Wiafe-Addai B, Clegg-Lamptey JNA. Breast cancer in sub-Saharan Africa: Opportunities for
prevention. Breast Cancer Res Treat 2014;144:467-78. PMCID: PMC4023680.
78.
Agarwal D, Pineda S, Michailidou K, … Figueroa JD, … Milne RL. FGF receptor genes and
breast cancer susceptibility: Results from the Breast Cancer Association Consortium. Br J
Cancer 2014;110:1088-100. PMCID: PMC3929867.
79.
Milne RL, Herranz J, Michailidou K, … Figueroa JD, … Easton DF. A large-scale
assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and
42 461 controls from the breast cancer association consortium. Hum Mol Genet
2014;23:1934-46. PMCID: PMC3943524.
80.
Perry JR, Hsu YH, Chasman DI, … Figueroa JD, … Murray A. DNA mismatch repair gene
MSH6 implicated in determining age at natural menopause. Hum Mol Genet 2014;23:2490-7.
PMCID: PMC3976329.
81.
Sawyer E, Roylance R, Petridis C, … Figueroa J, … Garcia-Closas M. Genetic
predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet
2014;10:e1004285. PMCID: PMC3990493.
82.
Schoeps A, Rudolph A, Seibold P, … Figueroa JD, … Chang-Claude J. Identification of new
genetic susceptibility loci for breast cancer through consideration of gene-environment
interactions. Genet Epidemiol 2014;38:84-93. PMCID: PMC3995140.
83.
Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner
HG, Engelman CD, Klein BE, Titus LJ, Egan KM, Newcomb PA. Reproductive windows,
genetic loci, and breast cancer risk. Ann Epidemiol 2014;24:376-82. NIHMSID:
NIHMS577774.
Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, Hewitt SM,
Conway C, Lissowska J, Brinton LA, Prokunina-Olsson L, Dawson SJ, Caldas C, Easton D,
Chanock SJ, Figueroa JD. Breast cancer susceptibility risk associations and heterogeneity by
E-cadherin tumor tissue expression. Breast Cancer Res Treat 2014;1:181-7. NIHMSID:
NIHMS616634.
JDF-16
84.
Figueroa JD, Han SS, Garcia-Closas M, … Silverman DT. Genome-wide interaction study of
smoking and bladder cancer risk. Carcinogenesis 2014;35:1737-44. PMCID: PMC4123644.
85.
Milne R, Herranz J, Michailidou K, … Figueroa JD, … Easton DF. A large-scale assessment
of two-way SNP interactions in breast cancer susceptibility using 46,450 Cases and 42,461
controls from the Breast Cancer Association Consortium. Hum Mol Genet 2014;23:1934-46.
PMCID: PMC3943524.
86.
Johnson N, Dudbridge F, Orr N, … Figueroa JD, … Fletcher O. Genetic variation at CYP3A
is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer
Res 2014; May 26 (E-pub).
87.
Purrington KS, Slettedahl S, Bolla MK, … Figueroa JD, … Couch FJ. Genetic variation in
mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet.
2014 Nov 15;23(22):6034-46.
88.
Milne RL, Burwinkel B, Michailidou K, … Figueroa JD, … Easton DF. Common nonsynonymous SNPs associated with breast cancer susceptibility: Findings from the Breast
Cancer Association Consortium. Hum Mol Genet 2014 Nov 15;23(22):6096-111.
89.
Rotunno M, Sun X, Figueroa J, Sherman ME, Garcia-Closas M, Meltzer P, Williams T,
Schneider SS, Jerry DJ, Yang XR, Troester MA. Parity-related molecular signatures and
breast cancer subtypes by estrogen receptor status. Breast Cancer Res 2014 Jul 8;16(1):R74.
90.
Wang Z, Zhu B, Zhang M, … Figueroa JD, … Amundadottir LT. Imputation and subset
based association analysis across different cancer types identifies multiple independent risk
loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 2014; Jul 15
(E-pub).
91.
Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M,
Figueroa J, Rimm DL. ERβ splice variant expression in four large cohorts of human breast
cancer patient tumors. Breast Cancer Res Treat 2014;146:657-67.
92.
Yu K, Zhang H, Wheeler W, Horne HN, Chen J, Figueroa JD. A robust association test for
detecting genetic variants with heterogeneous effects. Biostatistics 2014; Jul 23 (E-pub).
93.
Lin WY, Camp NJ, Ghoussaini M, … Figueroa J, … Cox A. Identification and
characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with
breast cancer risk. Hum Mol Genet. 2015 Jan 1;24(1):285-98.
94.
Trabert B, Falk RT, Figueroa JD, Graubard BI, Garcia-Closas M, Lissowska J, Peplonska B,
Fox SD, Brinton LA. Urinary bisphenol A-glucuronide and postmenopausal breast cancer risk
in the Polish Breast Cancer Study. Cancer Causes Control 2014 Dec;25(12):1587-93.
95.
Ghoussaini M, Edwards SL, Michailidou K, … Figueroa JD, … Dunning AM. Evidence that
breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation via SNP
rs4442975. Nat Commun. 2014 Sep 23;4:4999.
JDF-17
96.
Sun X, Sandhu R, Figueroa JD, Gierach GL, Sherman ME, Troester MA. Benign breast
tissue composition in breast cancer patients: Association with risk factors, clinical variables,
and gene expression. Cancer Epidemiol Biomarkers Prev 2014 Dec;23(12):2810-8.
97.
Joshi AD, Lindstrom S, Husing A, Barrdahl M, VanderWeele TJ, Campa D, Canzian F,
Gaudet MM, Figueroa JD (writing group), …, Kraft P, on behalf of the Breast and Prostate
Cancer Cohort Consortium (BPC3). Additive interactions between GWAS-identified
susceptibility SNPs and breast cancer risk factors in the BPC3. Am J Epidemiol 2014 Nov
15;180(10):1018-27.
98.
Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, Yang XR,
Visscher D, Mies C, Anderson WF, Hewitt S, Khodr Z, Clare SE, Storniolo AM, Sherman
ME. Terminal duct lobular unit involution of the normal breast: implications for breast cancer
etiology. J Natl Cancer Inst. 2014 Oct 1;106(10).
99.
Matsuda K, Takahashi A, Middlebrooks CD, ...Figueroa JD,… Shuin T. Genome-wide
association study identified SNP on 15q24 associated with bladder cancer risk in Japanese
population. Hum Mol Genet. 2015 Feb 15;24(4):1177-84
100. Fu YP, Kohaar I, Moore LE, Lenz P, Figueroa JD (writing group), … Prokunina-Olsson L.
Translational implications of the 19q12 bladder cancer GWAS signal: association with
aggressive cancer and increased cyclin E expression in bladder tumors. Cancer Res. 2014 Oct
15;74(20):5808-18.
101. Lindström S, Thompson DJ, Paterson AD, … Figueroa J, … Tamimi RM, for the Markers of
Density (MODE) consortium. Genome-wide association study identifies multiple loci
associated with both mammographic density phenotypes and breast cancer risk: Results from
the MODE consortium. Nat Commun 2014 Oct 24;5:5303.
102. Khan S, Greco D, Michailidou K, … Figueroa J, … Nevanlinna H. MicroRNA related
polymorphisms and breast cancer risk. PLoS One 2014 Nov 12;9(11):e109973.
103. Casbas-Hernandez P, Sun X, Roman-Perez E, D'Arcy M, Sandhu R, Hishida A, McNaughton
K, Yang R, Amos KD, Sherman ME, Figueroa JD, Troester MA. Tumor intrinsic subtype is
reflected in cancer-adjacent benign tissue. Cancer Epidemiol Biomarkers Prev 2015
Feb;24(2):406-14.
104. †Khodr ZG, Sherman ME, Pfeiffer RM, Gierach GL, Brinton LA, Falk RT, Patel DA, Linville
L, Papathomas D, Clare SE, Visscher DW, Mies C, Hewitt SM, Storniolo AM, Rosebrock A,
Caban JJ, Figueroa JD. Circulating sex hormones and terminal duct lobular unit involution of
the normal breast. Cancer Epidemiol Biomarkers Prev 2014 Dec;23(12):2765-73.
105. Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL. Quantitative assessment of
miR34a as an independent prognostic marker in breast cancer. Br J Cancer 2015 Jan
6;112(1):61-8.
JDF-18
106. Howat W, Blows F, Brook M, … Figueroa JD, … Garcia-Closas M. Performance of
automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in
the Breast Cancer Association Consortium. Clin J Pathol (In press).
107. Spurdle A, Couch FJ, Parsons M, … Figueroa JD, … Goldgar DE. Refined histopathological
predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer
characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 2014
Dec 23;16(6):3419.
108. Kabisch M, Bermejo JL, Dunnebier T, … Figueroa JD, …Hamann U. The inner centromere
protein gene of the chromosomal passenger complex is a novel breast cancer susceptibility
gene. Carcinogenesis. 2015 Feb;36(2):256-71.
109. Orr N, Dudbridge F, Dryden N,… Figueroa J, … Peto J. Fine-mapping identifies two
additional breast cancer susceptibility loci at 9q31.2. Hum Mol Genet. 2015 May
15;24(10):2966-84.
110. Machiela MJ, Zhou W, Sampson JN,… Figueroa JD, … Chanock SJ. Characterization of
detectable large structural genetic mosaicism in the human genome. Am J Hum Genet. 2015
Mar 5;96(3):487-97.
111. Figueroa JD, Yang H, Garcia-Closas M, Davis S, Meltzer P, Lissowska J, Horne H, Sherman
ME, Lee M. Integrated analysis of DNA methylation, mRNA expression, and
immunohistochemistry data identifies a signature that predicts survival among ER-positive
breast cancers. Breast Cancer Res Treat 2015 Apr;150(2):457-66.
112. Michailidou K, Beesly J, Lindstrom S, … Figueroa JD,… Easton DF. Combined GWAS
analysis of more than 120,000 individuals identifies 17 novel susceptibility loci for breast
cancer. Nat Genet 2015 Apr;47(4):373-80.
113. Fagerholm R, Schmidt MK, Khan S, … Figueroa J,… Nevanlinna H. The SNP rs6500843 in
16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer
patients.Oncotarget. 2015 Apr 10;6(10):7390-407.
114. Lei J, Rudolph A, Moysich KB, … Figueroa J,… Chang-Claude J. Assessment of variation
in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of
estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Res. 2015 Feb
10;17:18.
115. Mavaddat N, Pharoah PPD, Michailidou K, … Figueroa JD, … Garcia-Closas M, for the
Breast Cancer Association Consortium. Prediction of breast cancer risk based on profiling
with common genetic variants. J Natl Cancer Inst 2015 Apr 8;107(5).
116. Guo Q, Schmidt MK, Kraft P, … Figueroa J, … Pharoah PD. Identification of novel genetic
markers of breast cancer survival. J Natl Cancer Inst. 2015 Apr 18;107(5).
117. Pirie A, Guo Q, Kraft P, … Figueroa J, … Schmidt MK. Common germline polymorphisms
JDF-19
associated with breast cancer-specific survival. Breast Cancer Res. 2015 Apr 22;17:58.
118. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and
Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck
A, … Figueroa J, … Goode EL. No clinical utility of KRAS variant rs61764370 for ovarian
or breast cancer. Gynecol Oncol. 2015 May 2.(E-pub)
119. Wang J*, Figueroa JD*, Wallstrom G, Barker K, Park J, Demirkan G, Lissowska J,
Anderson K, Qiu J, LaBaer J. Autoantibodies associated with basal-like breast cancers.
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1332-40. *These authors contributed
jointly to this work.
120. Darabi H, McCue K, Beesley J,… Figueroa JD,…Chenevix-Trench G. Polymorphisms in a
Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. Am
J Hum Genet 2015 Jul 2;97(1) 22-34.
121. Sobral-Leite M, Wesseling J, Smit VT, …Figueroa J, … Schmidt MK. Annexin A1
expression in a pooled breast cancer series: association with tumor subtypes and prognosis.
BMC Med. 2015 Jul 2;13:156.
122. Candido Dos Reis FJ, Lynn S, … Figueroa J, … Pharoah P. Crowdsourcing the General
Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine 2015 May 9;2
(7) 681-9.
123. Zhang B, Shu XO, Delahanty RJ, … Figueroa J, … Zheng W. Height and Breast Cancer
Risk: Evidence From Prospective Studies and Mendelian Randomization. J Natl Cancer Inst.
2015 Aug 20;107(11).
124. Jamshidi M, Fagerholm R, Khan S, … Figueroa J, … Nevanlinna H. SNP-SNP interaction
analysis of NF-κB signaling pathway on breast cancer survival. Oncotarget. 2015 Jul 22, Epub.
125. Figueroa JD, Koutros S, Colt JS, Kogevinas M, Garcia-Closas M, Real FX, Friesen MC,
Baris D, Stewart P, Schwenn M, Johnson A, Karagas MR, Armenti KR, Moore LE, Schned A,
Lenz P, Prokunina-Olsson L, Banday AR, Paquin A, Ylaya K, Chung JY, Hewitt SM,
Nickerson ML, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Malats N, Fraumeni
JF Jr, Chanock SJ, Chatterjee N, Rothman N, Silverman DT. Modification of Occupational
Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms. J Natl Cancer Inst.
2015 Sep 14;107(11).
126. Day FR, Ruth KS, Thompson DJ,… Figueroa J, … Murray A. Large-scale genomic analyses
link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1mediated DNA repair. Nat Genet. 2015 Nov;47(11): 1294-303.
127. Sampson JN*, Wheeler WA8, Yeager M*, Panagiotou O*, Wang Z*, Berndt SI*, Lan Q*,
Abnet CC*, Amundadottir LT*, Figueroa JD*, Landi MT*, Mirabello L*, Savage SA*,
JDF-20
Taylor PR*, Vivo ID*, McGlynn KA*, Purdue MP*, Rajaraman P*, … Chatterjee N.
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies
for Thirteen Cancer Types. J Natl Cancer Inst. 2015 Oct 12;107(12). *These authors
contributed jointly to this work.
128. Meeks HD, Song H, Michailidou K,… Figueroa J, … Goldgar DE. BRCA2 Polymorphic
Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer
Inst. 2015 Nov 19;108(2).
129. Lei J, Rudolph A, Moysich KB,… Figueroa J, … Chang-Claude J. Genetic variation in the
immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of
42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum
Genet. 2015 Nov 30, E-pub.
130. Figueroa JD, Middlebrooks C, Banday AR, … Rothman N. Identification of a novel
susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus
associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet
2015, In press.
EDITORIALS
1.
Figueroa JD, Brinton LA. Unraveling genes, hormones, and breast cancer. J Natl Cancer Inst
2012;104:641-2. PMCID: PMC3341311.
BOOK CHAPTERS AND OTHER NON-PEER REVIEWED
1.
Figueroa JD, Garcia-Closas M, Rothman N. Case studies: cumulative assessment of the role
of human genome variation in specific diseases - bladder cancer. In: Khoury M, Bedrosian S,
Gwinn M, Higgins J, Ioannidis J, Little J, eds. Human genome epidemiology, second edition:
Building the evidence for using genetic information to improve health and prevent disease.
Oxford: Oxford Scholarship Online 2010;299-325.
JDF-21